Recent Updates
Recently added Catalysts
CVRX Negative Sentiment Score: 20/100

CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Key Takeaway: CVRx, Inc. is currently under investigation by Bronstein, Gewirtz & Grossman, LLC for potential claims related to investor actions. The investigation follows an announcement from the Centers for Medicare and Medicaid Services regarding significant proposed cuts in reimbursement rates for the company's heart failure device, leading to a sharp decline in share price. Investors are encouraged to participate in the investigation if they have relevant information or purchased CVRx securities. The firm emphasizes that there will be no costs incurred by investors unless the case is successful.

Market Sentiment Analysis

CONCERNS & RISKS

  • CVRx's stock dropped over 38.5% following news of reduced reimbursement rates.
  • CMS proposed significant cuts in payment rates for CVRx's heart failure device.
  • The ongoing investigation may indicate potential mismanagement or negative events affecting investors.

Full Press Release Details

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. (“CVRx” or “the Company”) (NASDAQ: CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/CVRX.
Investigation Details
On July 10, 2024, the Centers for Medicare and Medicaid Services (“CMS”) issued proposed payment rates for outpatient and Ambulatory Surgical Center (“ASC”) services. Piper Sandler issued a note indicating that under the CMS rules, reimbursement for CVRx’s heart failure device would fall by 38.1% for ASC services and by 32.9% for hospital outpatient services. Based on this news, shares of CVRx dropped over 38.5% on the same day.
If you are aware of any facts relating to this investigation or purchased CVRx securities, you can assist this investigation by visiting the firm’s site: bgandg.com/CVRX. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Tags

Frequently Asked Questions

What is the CVRx investigation about?

Bronstein, Gewirtz & Grossman, LLC is investigating claims for CVRx investors due to a significant stock drop.

How much did CVRx shares drop?

On July 10, 2024, CVRx shares fell over 38.5% following CMS reimbursement changes.

What significant change affected CVRx's device reimbursement?

CMS proposed reductions of 38.1% for ASC and 32.9% for outpatient services for CVRx.

Is there a cost to participate in the investigation?

No, there is no cost. The firm operates on a contingency fee basis.

How can CVRx investors get involved in the investigation?

Investors can visit bgandg.com/CVRX to share information and support the investigation.

Last updated: Aug 7, 2024